CrystecPharma is pleased to announce its participation in the Drug Delivery to the Lungs (DDL) 2025 conference, taking place in Edinburgh from 10–12 December.
DDL is a leading annual event that brings together scientists, researchers, and industry professionals dedicated to advancing the development of medicines for inhalation.
CrystecPharma CEO, Paul Thorning, will be attending the conference to discuss how the company’s mSAS® particle engineering platform enables the creation of optimised particles for inhaled delivery, enhancing stability, solubility, and overall performance of inhaled therapeutics.
To arrange a meeting with Paul during the conference, please contact wendy.towler@crystecpharma.com.